Literature DB >> 31774589

Engineering the serpin α1 -antitrypsin: A diversity of goals and techniques.

Benjamin M Scott1,2, William P Sheffield3,4.   

Abstract

α1 -Antitrypsin (α1 -AT) serves as an archetypal example for the serine proteinase inhibitor (serpin) protein family and has been used as a scaffold for protein engineering for >35 years. Techniques used to engineer α1 -AT include targeted mutagenesis, protein fusions, phage display, glycoengineering, and consensus protein design. The goals of engineering have also been diverse, ranging from understanding serpin structure-function relationships, to the design of more potent or more specific proteinase inhibitors with potential therapeutic relevance. Here we summarize the history of these protein engineering efforts, describing the techniques applied to engineer α1 -AT, specific mutants of interest, and providing an appended catalog of the >200 α1 -AT mutants published to date.
© 2019 The Protein Society.

Entities:  

Keywords:  protein design; protein engineering; proteinase inhibitor; serpin; α1-antitrypsin; α1-proteinase inhibitor

Mesh:

Substances:

Year:  2019        PMID: 31774589      PMCID: PMC7096715          DOI: 10.1002/pro.3794

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  157 in total

1.  Production of recombinant serpins in Escherichia coli.

Authors:  Mary C Pearce; Lisa D Cabrita
Journal:  Methods Enzymol       Date:  2011       Impact factor: 1.600

Review 2.  Furin at the cutting edge: from protein traffic to embryogenesis and disease.

Authors:  Gary Thomas
Journal:  Nat Rev Mol Cell Biol       Date:  2002-10       Impact factor: 94.444

Review 3.  The future of bypassing agents for hemophilia with inhibitors in the era of novel agents.

Authors:  A D Shapiro; I S Mitchell; S Nasr
Journal:  J Thromb Haemost       Date:  2018-10-11       Impact factor: 5.824

4.  Cellular internalization and degradation of antithrombin III-thrombin, heparin cofactor II-thrombin, and alpha 1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein.

Authors:  M Z Kounnas; F C Church; W S Argraves; D K Strickland
Journal:  J Biol Chem       Date:  1996-03-15       Impact factor: 5.157

Review 5.  Serpins are suicide substrates: implications for the regulation of proteolytic pathways.

Authors:  P A Patston; P G Gettins; M Schapira
Journal:  Semin Thromb Hemost       Date:  1994       Impact factor: 4.180

6.  The circulating proteinase inhibitor α-1 antitrypsin regulates neutrophil degranulation and autoimmunity.

Authors:  David A Bergin; Emer P Reeves; Killian Hurley; Rebecca Wolfe; Ramia Jameel; Sean Fitzgerald; Noel G McElvaney
Journal:  Sci Transl Med       Date:  2014-01-01       Impact factor: 17.956

7.  Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1.

Authors:  L Shapiro; G B Pott; A H Ralston
Journal:  FASEB J       Date:  2001-01       Impact factor: 5.191

8.  Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14.

Authors:  Loyse M Felber; Christoph Kündig; Carla A Borgoño; Jair R Chagas; Andrea Tasinato; Patrice Jichlinski; Christian M Gygi; Hans-Jürg Leisinger; Eleftherios P Diamandis; David Deperthes; Sylvain M Cloutier
Journal:  FEBS J       Date:  2006-06       Impact factor: 5.542

9.  Inhibitory activity and conformational transition of alpha 1-proteinase inhibitor variants.

Authors:  A J Schulze; R Huber; E Degryse; D Speck; R Bischoff
Journal:  Eur J Biochem       Date:  1991-12-18

10.  Effects of mutations in the hinge region of serpins.

Authors:  P C Hopkins; R W Carrell; S R Stone
Journal:  Biochemistry       Date:  1993-08-03       Impact factor: 3.162

View more
  7 in total

Review 1.  Engineering the serpin α1 -antitrypsin: A diversity of goals and techniques.

Authors:  Benjamin M Scott; William P Sheffield
Journal:  Protein Sci       Date:  2019-12-09       Impact factor: 6.725

2.  Accelerated Wound Border Closure Using a Microemulsion Containing Non-Inhibitory Recombinant α1-Antitrypsin.

Authors:  Alon Gimmon; Lior Sherker; Lena Kojukarov; Melodie Zaknoun; Yotam Lior; Tova Fadel; Ronen Schuster; Eli C Lewis; Eldad Silberstein
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

3.  Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant.

Authors:  Mostafa Hamada; Varsha Bhakta; Sara N Andres; William P Sheffield
Journal:  Front Cardiovasc Med       Date:  2021-03-19

4.  Deep mutational scanning of the plasminogen activator inhibitor-1 functional landscape.

Authors:  Zachary M Huttinger; Laura M Haynes; Andrew Yee; Colin A Kretz; Matthew L Holding; David R Siemieniak; Daniel A Lawrence; David Ginsburg
Journal:  Sci Rep       Date:  2021-09-22       Impact factor: 4.379

5.  Potential Use of Alpha-1 Anti-trypsin in the Covid-19 Treatment.

Authors:  Fernanda Martini; Monica De Mattei; Carlo Contini; Mauro G Tognon
Journal:  Front Cell Dev Biol       Date:  2020-10-23

6.  Using serpins cysteine protease cross-specificity to possibly trap SARS-CoV-2 Mpro with reactive center loop chimera.

Authors:  Mohamad Aman Jairajpuri; Shoyab Ansari
Journal:  Clin Sci (Lond)       Date:  2020-09-18       Impact factor: 6.124

7.  Identification of an alpha-1 antitrypsin variant with enhanced specificity for factor XIa by phage display, bacterial expression, and combinatorial mutagenesis.

Authors:  Varsha Bhakta; Mostafa Hamada; Amy Nouanesengsy; Jessica Lapierre; Darian L Perruzza; William P Sheffield
Journal:  Sci Rep       Date:  2021-03-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.